Irinotecan Kabi

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Kabi, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It is indicated for the treatment of metastatic colorectal cancer in adult patients, typically as part of combination chemotherapy regimens.

GNH USA supplies Irinotecan Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with distribution aligned to EU regulatory standards and cold‑chain logistics where required. The company ensures product integrity through validated packaging and rigorous quality control.

Irinotecan Kabi is a topoisomerase I inhibitor used in colorectal cancer therapy.

Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine‑based regimens. Small cell lung cancer: provides benefit as second‑line therapy in combination with other agents.

Irinotecan Kabi may cause a range of adverse reactions.

Common Side Effects: - Neutropenia: decreased white blood cell count increasing infection risk. - Diarrhea: often severe and may require antidiarrheal therapy. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment. - Fatigue: generalized tiredness. - Anemia: reduced red blood cell levels.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils, requiring urgent care. - Severe colitis: life‑threatening inflammation of the colon. - Hepatic toxicity: elevated liver enzymes or jaundice. - Hypersensitivity reactions: rash, bronchospasm, or anaphylaxis. - Pulmonary toxicity: interstitial pneumonitis or fibrosis. - Hemorrhagic events: bleeding due to thrombocytopenia.

Use of Irinotecan Kabi requires careful monitoring and patient assessment.

Dose adjustment in renal impairment: reduce dose based on renal function. Monitor blood counts: perform regular CBC to detect neutropenia. Assess liver function: adjust for hepatic impairment. Avoid in patients with known hypersensitivity to irinotecan or its components. Pregnancy and lactation: use only if benefits outweigh risks; limited data. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan Kabi can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase toxicity. - Co‑administration with UGT1A1 inhibitors (e.g., atazanavir) can raise SN‑38 levels. - Combination with other myelosuppressive agents may cause severe bone marrow suppression.

Moderate Interactions (Monitor Closely): - Concurrent use with anticoagulants may increase bleeding risk. - Use with other antidiarrheal agents may mask symptoms. - Combination with drugs affecting electrolyte balance may require monitoring.